MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 886 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CK1δ-IN-9
CAS:<p>CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.</p>Fórmula:C16H12FN5Forma y color:SolidPeso molecular:293.298SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Fórmula:C23H22ClN7O2Forma y color:SolidPeso molecular:463.92MCB-22-174
CAS:MCB-22-174 is a potent agonist of Piezo1 with an EC50 value of 6.28 µM. It activates Ca2+-related extracellular signal-regulated kinase and calcium-calmodulin (CaM)-dependent protein kinase II (CaMKII) pathways, and it promotes mesenchymal stem cell osteogenic differentiation, indicating its potential application in the study of disuse osteoporosis (OP).Fórmula:C16H14DCl2N5OS2Peso molecular:429.37p38-α MAPK-IN-10
CAS:<p>p38-α MAPK-IN-10 (Compound 6) is an inhibitor of p38α, with an IC50 value of 4 nM.</p>Fórmula:C27H34Cl2N6Forma y color:SolidPeso molecular:513.505HPK1-IN-55
CAS:<p>HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.</p>Fórmula:C30H34N8O3Forma y color:SolidPeso molecular:554.643p38-α MAPK-IN-9
CAS:<p>p38-α MAPK-IN-9 (Compound 25a) is a p38-α MAPK inhibitor with a Ki value of 0.057 nM. It effectively inhibits LPS-induced TNFα production in hPBMC cells, exhibiting an IC50 of 18 nM.</p>Fórmula:C19H20N8O2Forma y color:SolidPeso molecular:392.414KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Fórmula:C31H34N8O2Forma y color:SolidPeso molecular:550.65pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Fórmula:C29H30ClF3N6O3SForma y color:SolidPeso molecular:635.10KRAS G12D inhibitor 3
CAS:<p>KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less than</p>Fórmula:C34H31ClF3N5O2Forma y color:SolidPeso molecular:634.09Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Fórmula:C36H39ClFN7O4Forma y color:SolidPeso molecular:688.191MRTX849 ethoxypropanoic acid
CAS:<p>MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.</p>Fórmula:C37H43ClFN7O5Forma y color:SolidPeso molecular:720.24KRAS G12D inhibitor 12
<p>KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)</p>Fórmula:C23H21ClFN5O3Forma y color:SolidPeso molecular:469.9INS018 055
CAS:<p>INS018 055 (TNIK&amp;MAP4K4-IN-2) is a TNIK and MAP4K4 inhibitor with anti-fibrotic activity.</p>Fórmula:C27H30FN7OPureza:98.53%Forma y color:SolidPeso molecular:487.57NDI-101150
CAS:<p>NDI-101150 (NMBS-2) is an HPK1 inhibitor with antitumor activity, inhibiting BLNK phosphorylation, and used in metastatic solid tumor research.</p>Fórmula:C27H27FN6O2Pureza:99.65%Forma y color:SolidPeso molecular:486.54Emprumapimod
CAS:<p>Emprumapimod, an oral p38α MAPK inhibitor, targets RPMI-8226 cells, curbs LPS-induced IL-6; IC50: 100 pM; for cardiomyopathy, acute pain.</p>Fórmula:C24H29F2N5O3Pureza:99.21% - >99.99%Forma y color:SolidPeso molecular:473.52Rineterkib
CAS:<p>Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.</p>Fórmula:C26H27BrF3N5O2Pureza:99.73%Forma y color:SolidPeso molecular:578.42Omtriptolide
CAS:<p>Omtriptolide, triptolide purified from the Chinese herb, is a water-soluble derivative prodrug.</p>Fórmula:C24H28O9Pureza:98%Forma y color:SolidPeso molecular:460.479Ravoxertinib hydrochloride
CAS:<p>Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).</p>Fórmula:C21H19Cl2FN6O2Pureza:98%Forma y color:SolidPeso molecular:477.32CMK
CAS:<p>CMK, an RSK2 kinase inhibitor, shows similar potency but less chemical stability compared with FMK.</p>Fórmula:C18H19ClN4O2Forma y color:SolidPeso molecular:358.82PLX7922
CAS:<p>PLX7922, a RAF inhibitor, demonstrates binding affinity with BRAF V600E and exhibits inhibitory effects on pERK in BRAF V600E cell lines, while inducing pERK activation in mutant NRAS cell lines.</p>Fórmula:C20H25FN6O2S2Forma y color:SolidPeso molecular:464.58
